Overexpression of SRRM1 has been associated previously with poor prognosis in prostate cancer (55) and silencing of SRRM1 was shown to reduce cell proliferation through a reduction of AKT phosphorylation levels and an increased expression of PTEN, a well-known tumor suppressor (55). Here, AKT1 is linked to prostate carcinoma.